Premium
Hemangiomas: new insight and medical treatment
Author(s) -
Neri Iria,
Balestri Riccardo,
Patrizi Annalisa
Publication year - 2012
Publication title -
dermatologic therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.595
H-Index - 68
eISSN - 1529-8019
pISSN - 1396-0296
DOI - 10.1111/j.1529-8019.2012.01481.x
Subject(s) - medicine , involution (esoterism) , infantile hemangioma , propranolol , systemic therapy , hemangioma , first line treatment , medical therapy , dermatology , pediatrics , intensive care medicine , surgery , chemotherapy , cancer , politics , breast cancer , political science , law
Infantile hemangiomas ( IHs ) are the most common tumors of infancy and are usually characterized by a pattern of rapid proliferation, followed by a slower period of involution. In most cases, IHs do not require any treatment because they spontaneously regress over the years. However, in a minority of patients, a therapy is mandatory and should be started early to avoid functional and esthetic impairment or even severe systemic complications. Currently, no medications exist that are specifically labeled to treat his ; however, because the serendipitous discovery of the efficacy of propranolol in the treatment of IHs at the D ermatologic D epartment of the U niversity of B ologna, β‐blocker therapy has become the first‐line therapy in severe and/or complicated hemangiomas. This is a practical review reporting our approach to IHs in our daily practice.